Nuvectis Pharma, Inc. NVCT Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Nuvectis Pharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Nuvectis Pharma, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nuvectis Pharma, Inc.'s retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nuvectis Pharma, Inc.'s retained earnings?
- Nuvectis Pharma, Inc. (NVCT) reported retained earnings of -$105.74M in Q1 2026.
- How has Nuvectis Pharma, Inc.'s retained earnings changed year-over-year?
- Nuvectis Pharma, Inc.'s retained earnings decreased by 34.6% year-over-year, from -$78.58M to -$105.74M.
- What is the long-term trend for Nuvectis Pharma, Inc.'s retained earnings?
- Over 4 years (2021 to 2025), Nuvectis Pharma, Inc.'s retained earnings has grown at a 66.7% compound annual growth rate (CAGR), from -$12.9M to -$99.69M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.